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Aims: The objective of our study was to assess the effects of orthostatic challenge on the
coagulation system in patients with a history of thromboembolic events and to assess
how they compared with age-matched healthy controls.
Methods: Twenty-two patients with histories of ischemic stroke and 22 healthy
age-matched controls performed a sit-to-stand test. Blood was collected prior to- and at
the end of- standing in the upright position for 6 min. Hemostatic profiling was performed
by determining thrombelastometry and calibrated automated thrombogram values,
indices of thrombin generation, standard coagulation times, markers of endothelial
activation, plasma levels of coagulation factors and copeptin, and hematocrit.
Results: Orthostatic challenge caused a significant endothelial and coagulation
activation in patients (Group 1) and healthy controls (Group 2): Plasma levels
of prothrombin fragment F1+2 were increased by approximately 35% and
thrombin/antithrombin-complex (TAT) increased 5-fold. Several coagulation variables
were significantly altered in Group 1 but not in Group 2: Coagulation times (CTs) were
significantly shortened and alpha angles, peak rate of thrombin generation (VELINDEX),
tissue factor (TF) and copeptin plasma levels were significantly increased (comparison
between standing and baseline). Moreover, the shortening of CTs and the rise of
copeptin plasma levels were significantly higher in Group 1 vs. Group 2 (comparison
between groups).
Conclusion: The coagulation system of patients with a history of ischemic stroke can be
more easily shifted toward a hypercoagulable state than that of healthy controls. Attentive
and long-term anticoagulant treatment is essential to keep patients from recurrence of
vascular events.
Keywords: thrombin, thrombosis, tissue factor, stroke/prevention, standing, orthostasis, coagulation, thrombo-
embolism
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INTRODUCTION
Several studies have reported that an orthostatic challenge
activates the coagulation system. Both active and passive standing
are associated with (i) pooling of blood in the legs, (ii) increased
transmural pressure, (iii) increased shear stress, as well as (iv)
endothelial activation in the lower extremities, associated with
(v) release of procoagulant glycoproteins, e.g., Tissue Factor
(TF) (Masoud et al., 2008; Cvirn et al., 2012; Haider et al.,
2013). All these studies have been performed in healthy young
controls. Despite coagulation activation, no cases of thrombosis
have been reported in these persons. It, therefore, appears that
an orthostatic challenge, induced by either active or passive
standing, does not provoke thromboembolic events in healthy
controls. However, orthostatic challenge-induced coagulation
activation might constitute a problem for patients at an already
elevated risk for vascular events, for example, ischemic stroke.
We, therefore, wanted to investigate the influence of
orthostatic challenge on the coagulation system in patients with
a history of ischemic stroke. In our study, 22 older patients,
who had recovered from ischemic stroke, performed a sit-to-
stand test, a suitable model for orthostatic challenge. Twenty-two
healthy age-matched controls served as controls.
Hemostatic profiling was carried out in both whole blood and
platelet poor plasma samples. The clot formation process was
monitored using TF-triggered thrombelastometry. Thrombin
generation was assessed by means of calibrated automated
thrombography (CAT), and by the determination of plasma
levels of prothrombin fragment 1+2 (F1+2) and thrombin-
antithrombin complexes (TAT). For further assessment
of orthostatic challenge-induced coagulation activation,
we measured prothrombin times (PT), activated partial
thromboplastin times (APTT), plasma levels of FII, FVII,
FVIII, protein C, and protein S. In order to evaluate orthostatic
challenge-induced endothelial activation, we determined plasma
levels of TF and of tissue-plasminogen activator as well as
of nitric oxide. Since nitric oxide has a very short half-life,
it is very difficult to determine nitric oxide content in whole
blood samples. We therefore measured nitrite + nitrate levels,
the major stable metabolites of nitric oxide, which can be
quantitatively determined (Romitelli et al., 2007).
It has been shown that standing is associated with
hemoconcentration due to the transfer of intravascular fluid
from the blood to the surrounding tissue (Hinghofer-Szalkay
and Moser, 1986; Jacob et al., 2005). We therefore determined
hematocrit values in pre- and post-orthostatic challenge blood
samples to compare the hemoconcentration effect of orthostatic
loading (standing) in both groups. Plasma volume changes were
calculated from hematocrit, as described by Masoud et al. (2010).
Moreover, copeptin levels have been shown to be sensitive
surrogate markers for the release of arginine-vasopressin, which
Abbreviations: APTT, Activated partial thromboplastin time; ETP, Endogenous
thrombin potential; CAT, calibrated automated thrombography; CFT, clot
formation time; CT, coagulation time; F 1+2, prothrombin fragment 1+2;
INR, international ratio; MCF, maximum clot firmness; PT, prothrombin time;
SD, standard deviation; TAT, thrombin/antithrombin-complex; TF, tissue factor;
VELINDEX, peak rate of thrombin generation.
is associated with orthostatic challenge (Goldsmith, 1989; Choi
et al., 2015). We therefore determined levels of copeptin in pre-
and post-orthostatic challenge plasma samples of the two groups
in order to evaluate the orthostatic challenge-response on the
hormonal levels.
MATERIALS AND METHODS
Subjects and Experimental Design
Twenty-two patients who had recovered from ischemic stroke
and 22 healthy controls performed a sit-to-stand test. The
patients had recovered from (their first) mild stroke syndromes
(NIHSS: 1–3), which occurred not longer than 12 months
before the measurements that were carried out in this study.
The patients and healthy controls characteristics are shown in
Table 1.
After 5min of sitting still, a blood sample (baseline) was
collected from the antecubital vein. Subsequently, test subjects
were assisted into the upright positon for 6min; another blood
sample was then withdrawn from the vein (standing sample).
While standing, test subjects kept their eyes open and did not
alter foot placement.
Experiments were carried out in a room with minimal
ambient noise. The room temperature was maintained between
23 and 25◦C and the experiments were carried out between 7
and 11 a.m. All control subjects underwent basic neurological
assessment prior to our investigations.
The Ethics Committee of the Medical University of Graz,
Austria approved this study (EK-Nr. 25-551 ex 12/13). Both
patients and healthy controls provided informed written consent
before taking part in the study.
Blood Sampling
Baseline Samples
Twelve milliliters of venous blood were collected in pre-citrated
Vacuette R© tubes, which contained 3.8% sodium citrate (Greiner
Bio-one GmbH, Kremsmünster, Austria). Additionally, 4mL of
venous blood was collected into EDTA- and aprotinin-treated
tubes to determine copeptin concentrations. Haematocrit and
thrombelastometry measurements were performed in citrated
whole blood samples. Subsequently, the remaining whole blood
underwent centrifugation at 2000 g for 20min in order to prepare
platelet poor plasma samples. The remainingmeasurements were
performed in platelet poor plasma samples.
Standing Samples
After the subjects spent 6min in an upright position,
venous blood samples were withdrawn in the same way-
and measurements performed- as described for the baseline
samples.
TF-Triggered Thrombelastometry Assay
The clot formation process was monitored using the
thrombelastometry coagulation analyser (ROTEM R©05, Matel
Medizintechnik, Austria). The following were measured: CT
(Coagulation time): which is time from adding trigger to
formation of initial fibrin formation; Clot formation time (CFT):
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TABLE 1 | Participants’ characteristics.
All patients Stroke group Control group P-value
(n = 44) (n = 22, Group 1) (n = 22, Group 2) (Group 1 vs. Group 2)
Gender, female/male 19/25 7/15 12/10 n.s.
Age (years), mean ± SD 63.8 ± 7.0 62.4 ± 6.7 65.2 ± 7.1 n.s.
Body mass index, mean ± SD, kg/m2 28 ± 7 27 ± 5 28 ± 5 n.s.
ANTICOAGULANT THERAPY
ASA (100 mg), n (%) 18 (41) 15 (68) 3 (14) 0.0003
Clopidogrel (75 mg), n (%) 6 (14) 6 (27) 0 (0) 0.0110
Antidiabetic therapy, n (%) 2 (5) 1 (4) 1 (4) n.s.
Antihypertensive therapy, n (%) 23 (52) 16 (73) 7 (32) 0.0074
Previous vascular events, n (%) (venous thromboembolism, MCI) 2 (5) 2 (10) 0 (0) <0.0001
VASCULAR RISK FACTORS
Arterial hypertension, n (%) 24 (55) 18 (82) 6 (27) 0.0003
Dyslipidemia, n (%) 21 (48) 16 (73) 5 (23) 0.0011
Diabetes mellitus, n (%) 2 (5) 1 (5) 1 (5) n.s.
Nicotine usage 4 (9) 3 (14) 1 (5) n.s.
Obesity > grade 1, n (%) 4 (9) 3 (14) 1 (5) n.s.
Atrial fibrillation, n (%) 4 (9) 4 (18) 0 (0) n.s.
NIHSS at baseline, median (range) 0 (0–3) 1 (0–3) 0 (0) <0.0001
A total of 44 individuals performed a sit-to-stand test. Group 1 comprised of 22 older patients who had recovered from ischemic stroke, 22 healthy age-matched controls served as
controls (Group 2). P-values were calculated by means of the Fischer’s exact test. ASA, acetylsalicylic acid; MCI, myocardial infarction; NIHSS, National Institutes of Health Stroke
Scale.
which is the time taken until the amplitude reaches 20mm;
Maximum clot firmness (MCF): which reflects clot stability;
Alpha angle: which indicates the velocity of fibrin built-up and
cross-linking. For this procedure, the volume of blood sample
required was 340 µL and clot formation was initiated by adding
40 µL of “trigger solution” (containing 0.35 pmol/L TF and
3mmol/L CaCl2, final concentration) to 300µL of citrated whole
blood (Sørensen et al., 2003).
Thrombin Generation Assessments via the
Automated Fluorogenic Measurements
CAT obtained from Thrombinoscope BV (Maastricht, the
Netherlands) was used to monitor Thrombin generation
curves (Hemker et al., 2003). Following laboratory values
were determined: Lag Time: which is the time preceding the
thrombin burst; Endogenous thrombin potential (ETP) and
peak height (Peak): Either of these reflect the amount of
thrombin being generated; ttPeak: time to peak; VELINDEX
[peak thrombin/(peak time− lag time)]: the peak rate of thrombin
formation; StartTail: the time at which no free thrombin is
measurable. Low amounts of trigger (5 pmol/L of TF) were used
for sensitive detection of thrombin formation.
Standard Laboratory Tests
BM/Hitachi 917 (Roche, Austria) was used to determine the
following: PT: expressed as International Normalized Ratio,
INR; APTT; plasma levels of FII; FVII; FVIII; protein C; and
protein S. ELISA kits (Behring Diagnostics GmbH, Marburg,
Germany) were used to measure F 1+2 levels in the plasma
and TAT. TF plasma levels were determined by applying
ACTICHROME Tissue Factor ELISA and tissue-plasminogen
activator concentrations were determined using the IMUBIND
tissue-plasminogen activator ELISA kit (American Diagnostica,
Pfungstadt, Germany).
Haematocrit and Blood Cell Counts
Sysmex KX-21 N Automated Haematology Analyzer from
Sysmex (Illinois, USA) was used to determine hematocrit and
blood cell counts.
Nitrite+Nitrate Plasma Levels
Two hundred microliters of plasma (baseline and standing
samples) were diluted with double-distilled water (1:2, vol/vol)
and loaded on pre-conditioned anion exchange columns
(Chromabond SB, Macherey-Nagel, Düren, Germany). After
a washing step with double-distilled water nitrite and nitrate
were eluted with 1mL 0.5 mol/L sodium chloride. In the eluates,
nitrite and nitrate were determined simultaneously by means
of HPLC analysis according to a previously published method
(Romitelli et al., 2007) but with some modifications. Briefly,
the HPLC consisted of a L-2200 autosampler, two L-2130 HTA
pumps, and a L-2450 diode array detector (all: VWR Hitachi,
VWR, Vienna, Austria). Separation was performed on a Hypersil
ODS column (5 µm; 250 × 4mm I.D.) with 10.0min isocratic
elution (buffer A: 0.1 mol/L NaH2PO4, pH = 5.5, containing 5.9
mmol/L tetrabutylammonium hydrogensulphate) followed by a
linear gradient to 20% buffer B (buffer B: 0.1 mol/L NaH2PO4,
pH = 5.5, containing 5.9 mmol/L tetrabutylammonium
hydrogensulphate/acetonitrile, 3:1, vol/vol) within another
10min. The injection volume of standard and sample solutions
was 40 µL. The absorbance at 205 nm was recorded. Data
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acquisition and subsequent analysis was done with the EZchrom
Elite (VWR) program. Retention time was ∼7.80min for nitrite
and∼14.5min for nitrate.
Concentration of Copeptin
Levels of copeptin were determined in heparinized plasma
samples by means of a sandwich enzyme immunoassay from
Wuhan USCN Business Co., Ldt (Houston, USA).
Statistics
IBM SPSS Statistics 23 (IBM, New York, USA) program was used
for statistical analyses. Differences in Table 1 between group 1
(patients recovered from stroke) and group 2 (healthy, age-
matched controls) were determined by means of the Fischer’s
exact test. The variables that were normally distributed were
tested by the Kolmogorov-Smirnov test and the Shapiro-
Wilk test. Values of p < 0.05 were considered as significant
deviations from the normal distribution. The median and the
interquartile range were calculated and presented in Tables 2–4
since most variables were not normally distributed. Furthermore,
to investigate the significance of differences before and after
orthostatic challenge, the Wilcoxon test was used for not
normally distributed variables. If variables were normally
distributed, a T-test for paired samples was applied. Finally,
TABLE 2 | Effects of orthostatic challenge on thrombelastometry and
thrombin generation values.
Baseline Post standing P-value
samples samples
THROMBELASTOMETRY
Group 1
Coagulation time (CT, s) 319 (178–524) 284 (168–530) <0.001a
Alpha angle (◦) 56 (24–72) 60 (23–79) 0.033a
Group 2:
Coagulation time (CT, s) 295 (153–726) 283 (115–487) n.s.b
Alpha angle (◦) 60 (30–75) 61 (33–75) n.s.a
CALIBRATED AUTOMATED THROMBOGRAM
Group 1
VELINDEX (nM/min) 8 (3–15) 10 (3–34) 0.011b
Group 2
VELINDEX (nM/min) 10 (4–17) 11 (3–21) n.s.a
THROMBIN GENERATION
Group 1
Prothrombin fragment 1+2 (pM) 293 (83–740) 387 (122–1000) <0.001b
Thrombin/antithrombin
complexes (µg/L)
4.3 (0.9–25.3) 19.7 (1.5–60) <0.001b
Group 2
Prothrombin fragment 1+2 (pM) 266 (167–519) 413 (221–1306) <0.001b
Thrombin/antithrombin
complexes (µg/L)
4.0 (1.7–25) 24.4 (3.8–60) <0.001b
Effects of orthostatic challenge in 22 older patients who had recovered from ischemic
stroke (Group 1) compared with 22 healthy age-matched controls (Group 2). Data are
expressed as median [interquartile range = Q1–Q3)]. P-values were calculated by means
of the t-test for paired samples (a) in case of normally distributed variables; otherwise the
Wilcoxon test (b) was applied.
to compare the changes between the patients and age-matched
healthy controls (Figures 1, 2), the difference between the
standing and the baseline value was calculated for each variable
(for example: CT-difference = CT-baseline − CT-standing).
To investigate the significance of these differences between the
patients and the control group, the T-test for independent
samples was applied in case of normal distribution. Otherwise,
if the new variables were not normally distributed, the Mann-
Whitney U-test (Tafeit et al., 2003) was used.
RESULTS
Detailed anthropometric measurements of all test subjects
are provided in Table 1. Although, a significantly higher
number of patients who had recovered from ischemic
stroke were treated with antiplatelet (acetylsalicylic acid
TABLE 3 | Effects of orthostatic challenge on selected coagulation times
and on indicators of endothelial activation.
Baseline samples Post standing samples P-value
STANDARD COAGULATION TIMES
Group 1
APTT (s) 36.8 (33.5–38.8) 34.8 (32.3–41.2) n.s.b
Group 2
APTT (s) 37.2 (32.8–39.0) 32.9 (30.8–36.3) <0.001a
ENDOTHELIAL ACTIVATION
Group 1
tPA (ng/mL) 10.1 (8.3–15.5) 9.4 (7.0–15.0) n.s.b
TF (pg/mL) 338 (282–531) 481 (372–591) 0.019b
Group 2
tPA (ng/mL) 7.3 (5.5–11.8) 9.7 (6.7–13.7) 0.035a
TF (pg/mL) 459 (362–799) 491 (302–1047) n.s.b
Effects of orthostatic challenge in 22 older patients who had recovered from ischemic
stroke (Group 1) compared with 22 healthy age-matched controls (Group 2). Data are
expressed as median [interquartile range = (Q1–Q3)]. P-values were calculated by means
of the t-test for paired samples (a) in case of normally distributed variables; otherwise
the Wilcoxon test (b) was applied. APTT, activated partial thromboplastin time; TF, tissue
factor; tPA, tissue-plasminogen activator.
TABLE 4 | Effects of orthostatic challenge on haematocrit and on copeptin
plasma levels.
Baseline samples Post standing samples P-value
HAEMATOCRIT (%)
Group 1 38.1 ± 2.9 38.7 ± 3.4 n.s.a
Group 2 38.0 ± 3.0 39.3 ± 3.1 0.002a
COPEPTIN (PG/ML)
Group 1 501 (289–748) 627 (308–860) 0.017a
Group 2 545 (388–1048) 470 (305–1089) n.s.b
Effects of orthostatic challenge in 22 older patients who had recovered from ischemic
stroke (Group 1) compared with 22 healthy age-matched controls (Group 2). Haematocrit
data are presented as mean ± SD, while copeptin data are expressed as median
[interquartile range = Q1–Q3)]. P-values were calculated by means of the t-test for paired
samples (a) in case of normally distributed variables; otherwise the Wilcoxon test (b) was
applied.
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and/or clopidogrel) and hypotensive drugs, the basal levels of
coagulation parameters were not significantly different between
the two groups with the exception of tissue-plasminogen
activator. The basal tissue-plasminogen activator levels were
significantly higher in the recovered stroke-patients group
(10.1 vs. 7.3 ng/mL, medians, p = 0.023). Unsurprisingly,
the number of previous vascular events and of vascular
risk factors was greater in patients when compared with
controls.
FIGURE 1 | Orthostatic challenge-induced shortening of
thrombelastometry-derived CTs in patients recovered from stroke
(Group 1) vs. healthy, age-matched controls (Group 2). A boxplot of
CT-differences for the two groups is shown. P-values were calculated by
means of the Mann-Whitney U-test. “*” is an outlier.
FIGURE 2 | Orthostatic challenge-induced rise of copeptin plasma
levels in patients recovered from stroke (Group 1) vs. healthy,
age-matched controls (Group 2). A bar diagram of copeptin-differences for
the two groups presenting means ± SDs is shown. P-values were calculated
by means of the t-test for independent samples.
Effects of Orthostatic Challenge on
Thrombelastometry Values
Two thrombelastometry values indicated an orthostatic challenge
induced activation of the coagulation parameters in patients but
not in healthy controls: CTs were shortened significantly and
alpha angles were raised in the post standing whole blood samples
(Table 2). The shortening of CTs (difference between standing
and baseline) was significantly higher in the stroke patients
(Group 1) compared with healthy controls (Group 2), shown in
Figure 1. CFT andMCF values were not altered by the orthostatic
challenge in either group.
Effects of Orthostatic Challenge on CAT
Values
CAT measurements indicated that orthostatic challenge, in
the patients but not in healthy controls, enhances the
capability of plasma to generate thrombin. VELINDEX values
were significantly increased in the post standing samples in
patients- indicating an increased velocity of thrombin formation-
compared to baseline samples (Table 2). No significant influence
of orthostatic challenge on all other CAT values (Lag time,
ETP, Peak, ttPeak, and StartTail) was observed in both groups.
Similarly, no significant differences were observed by comparing
the coagulation changes between the two groups.
Effect of Orthostatic Challenge on Levels
of F1+2 and TAT
F1+2 and TAT plasma levels indicate that orthostatic challenge
is associated with significant thrombin formation in both groups.
F1+2 as well as TAT values were markedly increased in
the standing samples compared to baseline in patients, and
approximately to the same extent in controls (Table 2).
Effects of Orthostatic Challenge on
Standard Coagulation Times
PT values indicated that orthostatic challenge is associated with
coagulation activation: PTs (expressed as INR) were significantly
shorter in the post challenge samples compared to baseline in
both groups. Figure 3 depicts a paired graph showing the PT
changes in the stroke recoverd patients and healthy controls
(Figures 3, 4; Kimura et al., 2011). APTTs were significantly
shortened by orthostatic challenge in healthy controls but not
in patients (Table 3). No significant differences were observed by
comparing the changes between the two groups.
Effects of Orthostatic Challenge on
Coagulation Factor Levels
Orthostatic challenge did not affect FII, FVII, FVIII, protein C
and protein S in both groups (data not shown).
Effects of Orthostatic Challenge on
Endothelial Activation
Orthostatic challenge appears to cause activation of the
endothelium in both patients and healthy controls. Tissue-
plasminogen activator plasma values were raised in the standing
samples compared to the baseline levels in healthy controls
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FIGURE 3 | Effects of orthostatic challenge on Prothrombin Time (INR). The figure depicts a paired graph comparing baseline [median (Q1–Q3): 0.98
(0.95–1.02)] and post standing values [median (Q1–Q3): 0.97 (0.94–1.00)] of PT (INR) in stroke recovered patients (P = 0.037).
but not in patients with previous ischemic stroke, whereas TF
concentrations were increased in the post standing sample in
patients but not in the healthy controls (Table 3). Nitrite +
nitrate plasma levels were not altered by orthostatic challenge in
either group (data not shown). As stated above, the basal levels
of tissue-plasminogen activator were significantly higher in the
recovered stroke patients group. No significant differences of
tissue-plasminogen activator or TF were observed by comparing
changes between the two groups.
Effects of Orthostatic Challenge on
Haematocrit/Plasma Volume
Orthostatic challenge was associated with hemoconcentration
in healthy controls but not in patients. The hematocrit was
increased in the post standing samples in healthy controls
(Table 4). Correspondingly, the percent changes in plasma
volume (calculated from hematocrit, according to Masoud et al.,
2010) were greater in controls vs. patients (5.34 vs. 2.50%, p =
0.002). No significant differences of hematocrit were observed by
comparing the changes between the two groups.
Effects of Orthostatic Challenge on
Copeptin Plasma Levels
The response to orthostatic challenge on the hormonal level
was significantly higher in patients compared with healthy
controls. The copeptin levels were greater in the post standing
samples in patients but not in healthy controls (Table 4).
The rise of copeptin levels (difference between standing and
baseline) was significantly higher in the recovered stroke patients
(Group 1) compared with healthy controls (Group 2), shown
in Figure 2.
DISCUSSION
In the present study we quantified coagulation changes in
response to orthostatic challenge (a sit-to-stand test) in
patients who had recovered from ischemic stroke as compared
with healthy, age-matched controls. Although, significantly
more stroke-patients were treated with antiplatelet drugs
(acetylsalicylic acid and/or clopidogrel), approximately same
basal levels of thrombelastometry-derived coagulation times in
both groups were found in our study. While acetylsalicylic
acid has been shown to possess only a limited capability
to affect thrombelastometry values (Trentalange and Walts,
1991; Luddington, 2005), clopidogrel can effectively prolong
platelet-fibrin clot formation (Gurbel et al., 2007). Marked
effects were found in patients loaded with 300 to 600mg. We
assume that this effect could not be observed in our study
since our post-stroke patients were receiving only 75mg of
clopidogrel.
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FIGURE 4 | Effects of orthostatic challenge on Prothrombin Time (INR). The figure depicts a paired graph comparing baseline [median (Q1–Q3 ): 0.97
(0.92–0.98)] and post standing values [median (Q1–Q3): 0.95 (0.91–0.98)] of PT (INR) in healthy age matched controls. (P = 0.042).
Our data show that orthostatic challenge is associated with
activation of the coagulation system. In both groups of test
subjects, prothrombin fragment 1+2 as well as thrombin/
antithrombin-complex were significantly increased and
prothrombin times were significantly shortened in the post
standing samples compared to baseline to approximately
the same extent. Activated partial thromboplastin times
(median) were also shortened due to the orthostatic challenge,
reaching significance only in the healthy control group. These
findings are in agreement with two other studies, which
investigated the effects of still standing on the coagulation
cascade (Masoud et al., 2008, 2010). While the results from
those studies were based on stationary standing periods
that varied from 15 to 60min, we observed that a short 6
min standing period also leads to a significant activation of
the coagulation system. Furthermore, we observed that this
activation of the coagulation is significantly more pronounced
in patients than in healthy controls. Clotting times, determined
by means of thrombelastometry, were significantly shorter
in the standing samples compared with baseline in patients
recovered from stroke but not in healthy controls. This
indicates that orthostatic challenge is associated with a shift
toward hypercoagulability in patients who had recovered from
ischemic stroke, but not in healthy controls. Accordingly,
alpha angles were significantly increased (compared to
baseline) by orthostatic challenge in patients but not in
healthy controls, indicating that orthostatic challenge apparently
leads to enhancement of fibrin built-up and cross-linking
in post-stroke patients but not in healthy controls. The
changes were approximately the same by comparing both
groups.
Moreover, peak rate of thrombin generation values,
determined by means of calibrated automated thrombography,
were greater in the standing samples in patients but not in healthy
controls. This also indicates a shift toward hypercoagulability in
patients recovered from stroke: orthostatic challenge seems to
be associated with accelerated thrombin formation. Again, the
changes were approximately the same when both groups were
compared.
Furthermore, we found that orthostatic challenge significantly
elevates plasma levels of Tissue Factor (a marker of endothelial
activation, Tilley and Mackman, 2006) in patients compared
to baseline. This also indicates an orthostatic challenge-
induced shift toward hypercoagulability in the stroke-patients
group, as Tissue Factor is the most important trigger
of the coagulation cascade (Manly et al., 2011). Again,
the changes were approximately the same across the two
groups.
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Plasma levels of tissue-plasminogen activator (another marker
of endothelial activation) in healthy controls increased due to
orthostatic challenge compared to baseline, indicating increased
fibrinolytic activity in the standing samples in this group.
However, we found no increase of tissue-plasminogen activator
in the patients group compared to baseline, indicating that
orthostatic challenge fails to activate the fibrinolytic system in
this group (Mazzolai et al., 2002). Again, the changes were
approximately the same across both groups.
Levels of another marker of endothelial activation, nitric
oxide (determined as nitrite + nitrate plasma levels), were
apparently not affected by orthostatic challenge. An explanation
might be that the elevated basal levels of nitrite + nitrate
in plasma (approximately 60 µM) (Rashid et al., 2003) mask
the relatively low amounts of nitric oxide (most likely in the
nanomolar range) produced in response to shear stress (Tian
et al., 2010).
Interestingly, orthostatic challenge was associated with
significant hemoconcentration in healthy controls (∼5%) but not
in the patient group. Apparently, the microvascular permeability
in the stroke-patients group is significantly lower than in
the control group. An explanation might be that 73% of the
patients, who had recovered from ischemic stroke, but only
32% of the healthy controls, were treated with hypotensive
drugs (primarily angiotensin-converting enzyme inhibitors).
Angiotensin-converting enzyme inhibitors could have led to the
decreases in the microvascular permeability via suppression of
angiotensin II formation (Pupilli et al., 1999; Newton et al.,
2005). Hematocrit changes were approximately the same when
comparing both groups.
Our results also indicate that recovered stroke-patients show
more hormonal responses to orthostatic challenge than healthy
controls: Plasma levels of copeptin were greater in the standing
samples (in comparison to baseline) in patients but not in
controls. Copeptin is a valid surrogate marker for arginine-
vasopressin release. Due to the arginine-vasopressin being a
synergistic component of the hypothalamo-pituitary-adrenal
axis, levels of arginine-vasopressin also reflect the participants
orthostatic stress response (Katan et al., 2009; Masoud et al.,
2010). Copeptin changes were significantly higher in Group 1
compared with Group 2 of test subjects.
We have recently observed that there is some degree of
autonomic dysfunction–as reflected in the heart rate variability
measurements–during orthostatic challenge even after 1 year of
recovery from stroke (Rodriguez et al., in press). As autonomic
dysfunction changes have been associated with orthostatic
intolerance and clot formation at the site of the vascular injury
(Lopez-Vilchez et al., 2009), it is not surprising that a greater
tendency toward clot formation was seen in our stroke patients.
Our results are also in agreement with the work of Davidoff and
colleagues (Davydov et al., 2015).
In conclusion, our data indicate that orthostatic challenge,
i.e., a simple sit-to-stand test, leads to a shift toward
hypercoagulability in healthy controls, and, to a significantly
higher extent, in patients who had recovered from ischemic
stroke. In addition to other studies showing coagulation
activation after prolonged quiet standing (15 up to 60min), we
show herein that significant coagulation activation occurs even
after 6min of still standing. In our study, protein C plasma
levels remained unchanged by orthostatic challenge; this is in
agreement with the findings of Masoud et al. (2008, 2010). Thus,
it appears that the anticoagulant protein C pathway fails to
neutralize the shift toward hypercoagulability (Masoud et al.,
2008, 2010).
On the assumption that this simple sit-to-stand test is a
valid method that exposes subjects to a procoagulant challenge,
our data suggest that the coagulation system of patients
with a history of ischemic stroke can be more easily shifted
toward a hypercoagulable state than that of healthy controls.
Thus, our findings may explain the frequent recurrence of
thrombotic events in recovered stroke-patients (Becattini et al.,
2012). Our data emphasize the importance of accurate, regular
and long-term anticoagulant treatment of patients with a
history of thrombosis. It has to be stated that, by absolute
numbers, the shift toward a hypercoagulable state in the stroke-
patients group is, although statistically significant, relatively
small. All coagulation values remained within their reference
values, as reported in a previous study (Lamprecht et al.,
2013).
Notably, we show herein that even a short-term orthostatic
challenge leads to significantly shortened standard coagulation
times, particularly Prothrombin Times. With specific regard to
the coagulation system, we could not find any literature that
deals with the amount of time a patient should remain seated
before providing blood coagulation assessments. From previous
studies it is known that orthostatic challenge induced fluid shifts
need about 30 min to return to baseline supine values (Hagan
et al., 1978; Hinghofer-Szalkay et al., 2008; Goswami et al.,
2012). Furthermore, using head-up-tilt and lower-body-negative
pressure (Cvirn et al., 2012), we observed that endothelial
activation (as assessed by tissue factor levels) returns to baseline
levels around 20 min after orthostatic challenge. As patients are
often standing/walking before they reach the consultation room,
we recommend that when carrying out assessment of coagulation
related parameters, patients should be allowed to rest in a seated
or supine position for at least 20–30min. This will help eliminate
the influence of changes in posture on such tests as Prothrombin
time.
WHAT IS KNOWN ON THIS TOPIC
• Orthostatic challenge causes hypercoagulation.
• Orthostatic challenge induced hypercoagulation has been
tested in healthy young subjects.
• Orthostatic challenge induced hypercoagulation has been
reported to occur during presyncope induced by head up tilt
and graded lower body negative pressure.
WHAT THIS PAPER ADDS
• Orthostatic challenge causes a significant coagulation
activation in patients who have had ischemic stroke more than
1 year prior.
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• Orthostatic challenge also shifts the hemostatic system toward
hypercoagulation- but to a lesser degree- in healthy older
persons.
• Long term anti-coagulant treatment is essential to keep
patients from recurrence of vascular events.
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